The startup develops therapeutic cell technologies for regenerative medicine, specifically targeting musculoskeletal-related diseases through its proprietary cell therapy platform. This approach addresses the unmet medical need for effective treatments in patients suffering from tissue injuries in the musculoskeletal system.

Yellowknife is a custom digital platform that enables vehicles to share and utilize data clusters, enhancing connectivity and functionality. This technology addresses the challenge of fragmented vehicle data management, allowing for more efficient use of resources and improved user experiences in mobility services.

The startup operates an online platform that enables patients and caregivers to compare medical services and fees from healthcare professionals worldwide. This platform connects hospitals and clinics with a global audience, facilitating informed healthcare decisions and improving access to quality medical advice.

Coenbio acquires and cultivates beneficial microbial strains to create core ingredients for the food and medicine industries. They leverage proprietary technology and a diverse microbial library to develop solutions for hair growth, liver and gut health, and metabolic disorders.

CUBIG provides an enterprise platform for generating, integrating, and analyzing AI-ready synthetic data across multimodal formats like text, image, and tabular data. The platform utilizes differential privacy to ensure zero raw data exposure, offering compliance and risk-free use for sensitive datasets. This enables organizations to unlock inaccessible data for richer, compliant analysis and collaboration across various industries.

The startup offers genetic analysis services that include testing for cancer, prenatal, rare disease, and individual genomes, utilizing advanced sequencing technologies to deliver personalized diagnostic insights. By providing accurate and affordable genomic data, the company enables healthcare providers to tailor treatment plans and improve patient outcomes.

GeneMedicine is developing next-generation viral immunotherapies to treat patients with refractory cancers. By utilizing engineered oncolytic viruses, the company aims to enhance immune responses against tumors, improving patient outcomes and quality of life.

The startup develops biopharmaceuticals utilizing next-generation protein degradation mechanisms to target previously undruggable proteins associated with rare diseases. Their approach provides advanced drug candidates for out-licensing or in-licensing opportunities in the global pharmaceutical market.

J2H Biotech develops small-molecule drugs targeting intractable rare diseases through precision chemistry and targeted protein degradation techniques. The company addresses the unmet medical needs of patients suffering from conditions that currently lack effective treatment options.

NetTargets utilizes AI-enhanced systems biology and mathematical modeling to provide interpretable predictions for drug discovery, significantly reducing the risk of clinical trial failures. By simulating causal biological networks, the company helps identify effective treatment strategies and optimize patient selection, addressing the high failure rates in drug development.

The startup develops therapeutic drugs that leverage the ubiquitin-proteasome system to regulate protein levels in the body. This approach targets diseases such as cancer by utilizing natural biological processes for protein degradation.

The startup develops voice recognition technology that automates call center interactions for restaurants and salons, enabling efficient order processing and customer management. By integrating AI image recognition, the system extracts necessary information, reducing manual input and improving operational efficiency.

The startup provides a platform that offers customized portfolio management tools for behavioral coaches, enabling them to tailor investment strategies based on individual client goals. This approach enhances asset allocation efficiency, allowing coaches to better support their clients' financial objectives.

Recens Medical develops precision cooling devices, including OcuCool® for ocular surface anesthesia and TargetCool® for targeted cryosurgery, utilizing advanced cryogenic technology to maintain low temperatures. These devices address the need for effective pain management and tissue destruction in medical procedures, enhancing patient comfort and procedural outcomes.

RideFlux develops a full-stack software solution for autonomous driving systems, utilizing advanced algorithms and machine learning to ensure safe and efficient transportation. The company addresses the need for reliable autonomous transport services, significantly reducing the risk of accidents and improving mobility options for users.

Soft Berry is an electric vehicle charging platform that utilizes advanced data analytics and management systems to optimize charging station accessibility and efficiency. The platform addresses the challenge of uneven charging infrastructure distribution, ensuring that electric vehicle users can easily locate and utilize charging stations across various regions.

Ziptoss provides a secure digital platform for signing housing contracts in South Korea, utilizing encryption technology to ensure transaction integrity and confidentiality. The platform eliminates fraud and logistical delays associated with traditional contract signing, offering a streamlined process for landlords and tenants.